Myelodysplastic syndrome with excess blasts – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Myelodysplastic syndrome with excess blasts – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation https://clinicaltrials.eu/trial/study-comparing-gilteritinib-and-midostaurin-with-chemotherapy-for-newly-diagnosed-acute-myeloid-leukemia-or-myelodysplastic-syndrome-with-flt3-mutation/ Wed, 29 Apr 2026 15:01:09 +0000 https://clinicaltrials.eu/trial/study-comparing-gilteritinib-and-midostaurin-with-chemotherapy-for-newly-diagnosed-acute-myeloid-leukemia-or-myelodysplastic-syndrome-with-flt3-mutation/ This clinical trial is focused on studying two diseases: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes with excess blasts-2 (MDS-EB2). These are types of blood cancers that affect the bone marrow and blood cells. The study is investigating the effectiveness of two treatments, gilteritinib and midostaurin, both of which are medications taken orally. Gilteritinib is also known by its code name, ASP2215. These treatments are being tested in combination with chemotherapy in patients who have a specific genetic mutation called the FLT3 mutation, which is known to affect the progression of these diseases.

The purpose of the study is to compare the effectiveness of gilteritinib and midostaurin when used alongside chemotherapy. Participants in the study will receive either gilteritinib or midostaurin, along with standard chemotherapy treatments. The study will include an initial phase of treatment to induce remission, followed by a consolidation phase to strengthen the remission, and then a maintenance phase lasting one year to help prevent the disease from returning. The study is designed to observe how well these treatments work in prolonging the time patients remain free from events like disease progression or relapse.

Throughout the study, participants will be monitored for their overall survival, which means the time they live from the start of the study, and for any side effects they may experience. The study will also look at how quickly patients recover their blood cell counts after each cycle of chemotherapy. The goal is to determine which treatment is more effective in managing these blood cancers in patients with the FLT3 mutation. The study is expected to continue until 2031, providing valuable information on the long-term benefits and safety of these treatments.

]]>